Global pharmaceutical markets are experiencing rapid growth and are projected to continue evolving in the coming years, particularly in the areas of research and development, manufacturing, and formulation. This growth can be attributed to various factors, including the increasing global population, a rise in chronic diseases such as infectious diseases, oncology, and cardiovascular disorders, as well as a significant increase in healthcare expenditures. Additionally, the pharmaceutical industry is witnessing a surge in collaborations, mergers, and acquisitions, further driving its expansion.
To keep up with this growing demand and to address various challenges, many pharmaceutical companies are turning to contract manufacturing organizations (CMOs). These companies rely on CMOs for their manufacturing needs, as they may lack well-equipped facilities, advanced technologies, or high containment capabilities. Even when they possess the necessary facilities, they may outsource production to CMOs to save time and have a backup manufacturing option. This increasing trend of outsourcing manufacturing to CMOs is beneficial for both pharmaceutical companies and the service providers. It allows pharmaceutical companies to focus on their core competencies while leaving the manufacturing responsibilities to specialized CMOs. This trend is favoring contract manufacturing service providers and is expected to increase the share in the pharmaceutical manufacturing market. Contract pharmaceutical manufacturing services are mainly focused on the manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).
According to analysis, the pharmaceutical contract manufacturing (PCM) global market is expected to grow at a mid single digit CAGR from 2023 to 2030 to reach $100,102.8 million by 2030. The factors such as increased trend of outsourcing and high uptake of small molecules drugs across diverse therapeutics are driving the pharmaceutical contract manufacturing global market. Whereas, patent expiration and increasing adoption of 505(b)(2) pathway of small molecules drugs, advanced technologies in API and FDF manufacturing, increasing R&D expenditures and Capacity and Capability Expansion in advanced Highly Potent APIs and Complex Molecules platforms are providing immense opportunities to the market. However, contamination of pharmaceutical products (API and FDF), pricing pressure for pharmaceutical contract manufacturing, requirement of highly skilled technicians, increasing biologics approvals and adoption in disease management, stringent regulatory policies, and environmental concerns are some of the factors that are hindering pharmaceutical contract manufacturing global market growth.
The pharmaceutical contract manufacturing global market is mainly segmented based on product, phase, application, and geography. The pharmaceutical contract manufacturing market based on product is segmented into API manufacturing and FDF manufacturing. API manufacturing segment held the largest revenue in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030. The FDF manufacturing segment is expected to grow at a mid single digit CAGR from 2023 to 2030.
The API manufacturing global market based on product type is sub-segmented into Branded API manufacturing and Generic API manufacturing. The Branded API manufacturing segment accounted for the largest revenue in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030. Generic API manufacturing segment is expected to grow at a high single digit CAGR from 2023 to 2030.
The FDF manufacturing global market based on dosage form is further classified into solid dosage form, injectable dosage form, and semi-solid liquid and gaseous dosage form. Solid dosage form segment accounted for the largest revenue in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030. The injectable dosage form is expected to grow at a double digit CAGR from 2023 to 2030. Among semi-solid, liquid, and gaseous dosage form, semisolids segment accounted for the largest revenue of $XX million in 2023 owing to the increased usage of semisolids such creams, lotions and gels due to increase in skin related diseases, and changing climatic conditions followed by liquid forms with $XX million and gaseous forms with $XX million in 2023. The solid dosage form market is further classified into tablets, capsules, and others such as powders and granules. Among these, tablets segment generated the largest revenue of $XX million in 2023 owing to its ease of formulation techniques, manufacturing, and ease of administration to all the age groups, whereas capsules segment generated the revenue of $XX million and other segment such as powder and granules generated the revenue of $XX million in 2023.
Pharmaceutical contract manufacturing global market based on phase is segmented into commercial manufacturing and clinical manufacturing. Commercial manufacturing segment contributed to the highest revenue in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030. Whereas, clinical manufacturing is expected to grow at a mid single digit CAGR from 2023 to 2030.
The pharmaceutical contract manufacturing market based on therapeutic applications is segmented into infectious diseases, cardiovascular diseases, oncology, central nervous system, pulmonary diseases, gastrointestinal diseases, endocrine diseases, metabolic diseases, genitourinary diseases, musculoskeletal diseases, and others (eye, ENT, dental, nephrology, hepatology, post-operative pain, dermatology and others). Among these applications, the infectious disease segment accounted for the largest revenue in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030. The oncology division is expected to grow at a high single digit CAGR from 2023 to 2030.
The pharmaceutical contract manufacturing market based on region is classified into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, and Others), and the Rest of the World (Brazil, Rest of Latin America and Middle East & others). North America accounts for the largest revenue of in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030 due to growing pharma R&D expenditure, increasing development of new drugs over the time, increasing approval of generics, presence of number of API manufacturing facilities for all regulated drug products, increasing scope of highly potent drugs, government support to expand the domestic pharmaceutical manufacturing facilities, rise in the patient pool with various types of chronic disorders, increasing strategic partnerships among pharma companies & contract manufacturers and launch of advanced CDMO services.
The Asia-Pacific region is expected to grow at a high single digit CAGR from 2023 to 2030. The factors such as increasing generic pharmaceuticals, number of pharma companies with a strong network of manufacturing facilities (For instance, India is home for more than 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities), increasing outsourcing with number of CMO’s and expanding manufacturing facilities (Europe has outsourced most of its productions to India and China to restrain labor costs and energy expenditure), increasing development of new pharma drugs, increasing government investment to support the pharma industry (For instance, in June 2021, Government announced an additional outlay of $26,578.3 million for the pharmaceutical PLI scheme in 13 key sectors such as active pharmaceutical ingredients, drug intermediaries and key starting materials), increasing disease population, raising investment by the companies to expand their capabilities are driving the pharmaceutical contract manufacturing market in the region.
Some of the major players are AbbVie Inc. (U.S.), Asymchem Laboratories (Tianjin) (China), Cambrex Corporation (U.S.), Curia (U.S.), Delpharm (France), Lonza Group (Switzerland), Porton Pharma Solutions Ltd (China), Recipharm (Sweden), Thermo Fisher Scientific (U.S.) and WuXi AppTec (China).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
- North America
- U.S.
- Rest of North America
- Europe
- Germany
- France
- Italy
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of APAC
- Rest of the World (RoW)
- Brazil
- Rest of Latin America
- Middle East and Others
Table of Contents
1 Executive Summary
Samples
LOADING...
Companies Mentioned
- AbbVie Inc.(AbbVie Contract Manufacturing)
- ACIC Pharmaceuticals
- Adare Pharmaceuticals
- Adragos Pharma GmbH
- Aenova Group GmbH
- AGC Inc. (AGC Pharma Chemicals)
- Agno Pharma
- Alcami Corporation, Inc
- Almac Group
- ANI Pharmaceuticals
- Aphena Pharma Solutions
- Ardena Holding NV
- Artesan Pharma GmbH
- Asymchem Laboratories (Tianjin) Co., Ltd
- Avara pharmaceutical services Inc.
- Axplora
- Bachem holding AG
- BioDuro-Sundia
- BioVectra Inc
- Bluepharma
- C.O.C. Farmaceutici Srl
- Cerbios Pharma S.A.
- ChemCon GmbH
- Chemineau
- CordenPharma International(Germany)
- Curia
- Custom pharma services
- Delpharm
- Dr. Reddy's Laboratories Ltd (Aurigene Pharmaceutical Services Limited)
- Elaiapharm SAS
- EUROAPI
- Eurofins Scientific
- Evonik Industries AG
- Fabbrica Italiana Sintetici S.p.A.
- Fuji Chemical Industry CO.,LTD(Japan)
- GAP Pharmaceuticals
- GP Pharm SA
- Grand River Aseptic Manufacturing
- Groupe Parima Inc.
- Heraeus Holding GmbH
- Hiray Pharma Solutions
- Hovione
- Icrom SpA
- JSC Grindeks (HBM pharma s.r.o)
- Jubilant Pharma
- Kwizda Pharma GmbH.
- LGM Pharma, LLC
- Lonza Group
- Merck KGAa
- Mikart, LLC
- Mint lifesciences Pvt Ltd.
- Neolpharma Inc.
- Neolpharma Pharmaceutical Group
- Nextar Chempharma Solutions Ltd.
- NextPharma Technologies Holding Limited
- Nipro Corporation
- Olon S.p.A.
- PCI Pharma Services
- Pfizer Inc. (Pfizer CentreOne)
- PharmaBlock Sciences Nanjing Inc
- Pharmaron Beijing Co., Limited
- Phyton biotech LLC
- PI Industries
- Pierre Fabre
- Pillar5 Pharma Inc
- Piramal Pharma Limited
- Polpharma Group B.V. (Polpharma API CDMO)
- Polypeptide
- Polypeptide group
- Porton Pharma Solutions Ltd
- PSM GmbH
- PYRAMID Laboratories, Inc.(U.S.)
- Quotient Sciences
- Recipharm AB
- Regis Technologies
- Rottendorf Pharma
- R-Pharm Germany GmbH
- Sai life science Ltd.
- Saurav Chemicals Ltd
- ScinoPharm Taiwan Ltd.
- Selkirk Pharma
- Seqens SAS
- SGS S.A. ( Quay Pharma)
- Siegfried Holdings AG
- SK pharmteco (AMPAC Fine Chemicals)
- Societal CDMO
- Solvias AG
- Stason Pharmaceuticals, Inc.(Western PharmSci)
- Sterling Pharma Solutions
- Surepharma Services Ltd
- Synokem Pharmaceuticals Ltd.
- Thermofisher Scientific (Patheon N.V.)
- UBI Pharma Inc.
- UPM Pharmaceuticals, Inc.
- Upperton Pharma Solutions
- Valpharma S.p.A
- Veranova
- Wuxi Apptec